Interstitial lung disease

6 trials 4 recruiting MedDRA PT
6 Registered trials
4 Recruiting
6 Unique sponsors
6 Unique IMPs
1 Commercial trials
Drug classes (ATC)
— ATC code not specified 3
L Oncology (ATC L) 2
N Neurology/Psychiatry (ATC N) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 3 substances
Immunosuppressant 1 substance
Calcineurin inhibitor 1 substance
Kinase inhibitor 1 substance
Phase III: 1 Phase II/III: 1 Phase II: 2 Phase I/II: 1 Phase IV: 1

Filter these 6 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 6 trials

Phase III

1 trial
  • Assistance Publique Hopitaux De Paris Academic
    AZATHIOPRINE; TACROLIMUS
    2024-511868-83-00 1 country 2021 n=76
    Recruiting

Phase II/III

1 trial
  • Centre Hospitalier Regional Universitaire De Tours Academic
    IMP not specified
    2022-501335-16-00 1 country 2023 n=126
    Recruiting

Phase II

2 trials
  • Avalyn Pharma Inc. Commercial
    PIRFENIDONE
    2024-515964-30-00 3 countries 2021 n=33
    Ended
  • Intergroupe Francophone De Cancerologie Thoracique Academic
    IMP not specified
    2025-522790-10-00 1 country n=108
    Pending

Phase I/II

1 trial
  • Medical University Of Gdansk Academic
    ALLOGENEIC WHARTON'S JELLY-DERIVED MESENCHYMAL STEM CELLS; NINTEDANIB; PIRFENIDONE
    2024-514433-38-00 1 country 2023 n=45
    Recruiting

Phase IV

1 trial
  • Aarhus University Hospital Academic
    MORPHINE SULFATE
    2023-503700-81-00 1 country 2024 n=110
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Avalyn Pharma Inc. Commercial 1 Phase II 0
Centre Hospitalier Regional Universitaire De Tours Academic 1 Phase II/III 1
Intergroupe Francophone De Cancerologie Thoracique Academic 1 Phase II 0
Assistance Publique Hopitaux De Paris Academic 1 Phase III 1
Aarhus University Hospital Academic 1 Phase IV 1
Medical University Of Gdansk Academic 1 Phase I/II 1
New trials by year
2021
2
2023
2
2024
1
← All indication landscapes